Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00303992 · ClinicalTrials.gov registry record · Phase 2

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
9
Enrollment target
1
Study location

NCT00303992: Completed Phase 2 study of Breast Cancer, sponsored by University of California, San Francisco.

NCT00303992 is a Phase 2 study of Breast Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 9 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00303992, a Phase 2 study of Breast Cancer, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with irinotecan may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving trastuzumab together with irinotecan works in treating patients with HER2/neu positive metastatic breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • BIOLOGICAL trastuzumab
  • DRUG irinotecan hydrochloride

Study Locations (1)

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2004-05
Est. Completion 2013-01
Phase Phase 2
University of California, San Francisco

1,713 total trials

What the finished NCT00303992 record still lists

NCT00303992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which trastuzumab is the first listed.

NCT00303992 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00303992 about?

NCT00303992 is a clinical study titled "Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer". RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in dif...

What is the current status of trial NCT00303992?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-05. Estimated completion is 2013-01.

What conditions does trial NCT00303992 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00303992?

The interventions under investigation include: trastuzumab (BIOLOGICAL), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00303992?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00303992 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00303992's enrollment target sits among peer trials

9 1190th of 1224 higher than 30 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00303992, the US trial registry maintained by the National Library of Medicine. NCT00303992 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.